Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
33.74
0.00 (0.00%)
Harmony Biosciences is a biopharmaceutical company focused on developing and commercializing innovative treatments for patients with neurological disorders
The company is dedicated to addressing unmet medical needs in this space, particularly in the areas of rare and complex conditions. By leveraging proprietary research and development capabilities, Harmony Biosciences aims to bring forth therapies that improve the quality of life for patients, while also advancing scientific understanding of neurological diseases. Their portfolio includes products targeting specific disorders, reflecting a commitment to enhancing patient outcomes through personalized and effective treatments.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences:
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced a record $201.3 million in net product revenues for the fourth quarter 2024, and full year 2024 net revenues of $714.7 million, ending the year with $576 million in cash, cash equivalents and investments on the balance sheet. The company has guided 2025 WAKIX® net revenues to $820 - $860 million, targeting a $1B+ opportunity with WAKIX in narcolepsy alone.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for the treatment of excessive daytime sleepiness (EDS) in adult patients with idiopathic hypersomnia (IH). Harmony’s 2025 net revenue guidance of $820-$860 million remains unchanged.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on February 25, 2025, at 8:30 a.m. ET to discuss the results.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this performance, the company is well positioned for a catalyst-rich 2025, with value-creating milestones anticipated every quarter. Harmony will be highlighting its catalysts for 2025 and other key milestones during its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 11:15 a.m. PT / 2:15 p.m. ET.
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQHRMY) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQHRMY) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQHRMY) concerning possible violations of federal securities laws.
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Zynerba Pharmaceuticals, Inc. (NasdaqCM: ZYNE) to Harmony Biosciences Holdings, Inc. (NasdaqGM: HRMY). Under the terms of the proposed transaction, shareholders of Zynerba will receive only $1.1059 in cash for each share of Zynerba that they own, plus one non-tradeable contingent value right per share, representing the right to receive potential additional payments of up to $140 million in the aggregate, subject to the achievement of certain clinical, regulatory and sales milestones. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
San Diego, CA -- (SBWIRE) -- 08/17/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Harmony Biosciences Holdings, Inc.
BALA CYNWYD, Penn., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, April 23, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against LivePerson, Inc. (NASDAQLPSN), and Harmony Biosciences Holdings, Inc. NASDAQ: HRMYNASDAQHRMY)
San Diego, CA -- (SBWIRE) -- 04/14/2023 -- An investigation was announced for investors of Harmony Biosciences Holdings, Inc. (NASDAQHRMY) shares over potential securities laws violations by Harmony Biosciences Holdings, Inc.
NEW YORK, April 02, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Nutanix, Inc. (NASDAQNTNX) and Harmony Biosciences Holdings, Inc. NASDAQ: HRMYNASDAQHRMY)
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQHRMY) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQHRMY) investors concerning the Company’s possible violations of federal securities laws.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (NASDAQHRMY) on behalf of Harmony stockholders. Our investigation concerns whether Harmony has violated the federal securities laws and/or engaged in other unlawful business practices.
